Risperidone-associated diabetes mellitus: a pharmacovigilance study. - Wikidata - wikimedia - TriplyDB

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

http://www.wikidata.org/entity/Q35160244

about

Selection of atypical antipsychotics for the management of schizophrenia.Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.Blood lactate levels in patients receiving first- or second- generation antipsychotics.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth Relationship of atypical antipsychotics with development of diabetes mellitus.Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Pharmacological treatment strategies for schizophrenia.Safety and tolerability of emerging pharmacological treatments for bipolar disorder.Emerging treatments for bipolar disorder: safety and adverse effect profiles.Association between antipsychotic drugs and diabetes.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Medical co-morbidity risk factors and barriers to care for people with schizophrenia.The metabolic effects of antipsychotic medications.Cardiovascular effects of antipsychotics.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.Weighing in: emergent diabetes mellitus and second-generation antipsychotics.Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Atypical antipsychotics and diabetic ketoacidosis: a review.Belgian consensus on metabolic problems associated with atypical antipsychotics.Olanzapine induced biochemical and histopathological changes after its chronic administration in rats.Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.Pharmacovigilance in the 21st century: new systematic tools for an old problem.

P2860

Q31037993-F8276DF4-6139-414B-905B-C32409A57697 Q33256430-8639F65A-C510-42ED-AB5C-9DA24FAEF0DE Q34595255-DB41C39F-EC7B-41B8-9B8E-AA02FA3AB862 Q34613859-CF9C9F68-CD8F-4B3F-B7AA-3546B1FBF253 Q34623350-465F26E3-B299-4DC5-983F-42A8D143036B Q35128405-0A57B069-17C4-47DD-98B0-C7EA3B2231C4 Q35591014-21B84D36-4B2C-4C48-A5B6-4B6B93C78B0B Q36040749-9CCDE30B-B5AF-4A3D-988C-89A480F205E8 Q36107179-94C3A7D8-F61E-4875-A09F-94DB84BDB8D0 Q36199036-9EF0C8CA-31DF-4EA9-A9B1-BEACB36F479A Q36364980-C4ED3D21-9BE1-493B-AFB4-EB50421E00DF Q36382695-7576D003-B982-4CD9-A723-6080659CCA92 Q36474147-99CADEC6-5562-416F-AF38-D47B6A04AE2F Q36546664-AF1D62E8-60DE-4D07-B153-316B0E5EBA16 Q36577856-B9AA1A33-CFC5-477C-98B9-547017D62E3A Q36870063-72543C77-4664-461E-9C68-784224FFA9A3 Q36893286-10A72932-5AC7-4033-BC87-16FB25724672 Q36929179-0B3A51E4-2DB9-4B43-BE68-3266118D4224 Q36929181-01F19012-5E95-4310-824B-7EA56EC9CAFC Q37060706-543FE443-D9EC-457E-ACD4-1111E00228A2 Q38076320-2986ABB0-B611-4E6B-A02F-608B18E50499 Q38220364-3AE5BA91-B080-4DA5-AF4B-4CC47C150D2F Q41663843-0424FA8B-915F-400C-BC07-AFD88CA385B8 Q42358277-24D0DDEE-A185-4F41-814D-B2DC8CA04AA0 Q44387572-144C5E13-9868-491C-9DE1-268F73FCF4F0 Q45087202-6BC9208D-860E-44DE-9687-93DD54326456

P2860

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

http://www.wikidata.org/entity/Q35160244

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@ast

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@en

type

label

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@ast

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@en

prefLabel

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@ast

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@en

P1433

Q35160244-3AC47FDD-46DC-487D-83D2-39A65F477ABF

P1476

Q35160244-7AD0C98A-B46C-469B-A0AD-8C87DF6AB759

P2093

Q35160244-0F3A7CE9-5BB3-4058-AB3A-F2B5149048F0

Q35160244-14DA84E9-4423-4C07-823B-F7E298DC2A89

Q35160244-28E8CF39-613B-4965-A5EF-2A447AE254DD

Q35160244-5F6F8407-4E9D-4718-BADB-A3B260CEC162

P2860

Q35160244-02411A69-3B1A-4EBC-ADBB-9D63121C5F77

Q35160244-07E204B4-6ABC-408C-8C79-47CECEF2E669

Q35160244-14D60A65-085A-4D83-B192-3CCC849717E8

Q35160244-306E43B9-AF1C-4457-BBAE-A3DC6BFEB62A

Q35160244-307866EC-3DB8-4EE3-9BA5-BBBCB8FA5E32

Q35160244-4176C076-8023-466F-9E5D-D2A2761FEFD3

Q35160244-48E37D8A-738C-4D71-8C4A-5998BEBACA52

Q35160244-49DF103A-4E1B-484D-B0E8-04DAC590EAE4

Q35160244-531144C3-ADA0-4145-A572-26055DEA06A5

Q35160244-58D6FD71-8E84-43C0-A759-DBAA4AA13B90

P304

Q35160244-6FFF0154-044C-47F2-810D-8FCC85E01CF8

P31

Q35160244-AE3ED129-476F-4C3F-A308-05F1930C2225

P356

Q35160244-5DBD0B5F-29AD-407D-B075-98210DEBA190

P407

Q35160244-2EFDA6EF-BC74-49DF-8A6A-1E497605349A

P433

Q35160244-A79CB6C0-0AC6-4490-B699-39238387A506

P478

Q35160244-53278527-05FE-4063-9625-3530D88C8DD3

P577

Q35160244-BB3B48C8-64A4-4453-803E-F54D393C7ED1

P698

Q35160244-90F68ECB-8F7F-4668-B091-7F827DC362FF

P356

PHCO.23.6.735.32178

P1433

Pharmacotherapy

P1476

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

@en

P2093

Bruce S Schneider

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Koller

http://www.w3.org/2001/XMLSchema#string

James T Cross

http://www.w3.org/2001/XMLSchema#string

P Murali Doraiswamy

http://www.w3.org/2001/XMLSchema#string

P2860

Timing of new black box warnings and withdrawals for prescription medications

1988 annual report of the American Association of Poison Control Centers National Data Collection System.

1990 annual report of the American Association of Poison Control Centers National Data Collection System.

Olanzapine-associated diabetes mellitus.

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.

Bodyweight gain and anticonvulsants: a comparative review.

1987 annual report of the American Association of Poison Control Centers National Data Collection System.

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine.

Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

Different effects of antipsychotic drugs on insulin release in vitro.

P304

735-744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.23.6.735.32178

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12820816

http://www.w3.org/2001/XMLSchema#string